相似文献
1
Cancer Chemotherapy: Combination with Inhibitors (Volume I).癌症化疗：与抑制剂联用（第一卷）
Cancers (Basel). 2024 Jan 31;16(3):607. doi: 10.3390/cancers16030607.
2
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.1990年和2010年20个年龄组中235种死因的全球和区域死亡率：全球疾病负担研究2010的系统分析
Lancet. 2012 Dec 15;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0.
3
Mortality by cause for eight regions of the world: Global Burden of Disease Study.世界八个地区按病因划分的死亡率：全球疾病负担研究
Lancet. 1997 May 3;349(9061):1269-76. doi: 10.1016/S0140-6736(96)07493-4.
5
Prospective study of one million deaths in India: rationale, design, and validation results.印度百万死亡病例前瞻性研究：基本原理、设计与验证结果
PLoS Med. 2006 Feb;3(2):e18. doi: 10.1371/journal.pmed.0030018. Epub 2005 Dec 20.
6
Cardiovascular Toxicity Related to Cancer Treatment.与癌症治疗相关的心血管毒性
J Cardiovasc Dev Dis. 2023 Jun 14;10(6):259. doi: 10.3390/jcdd10060259.
7
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.2017 年全球疾病负担研究：1990-2017 年 195 个国家和地区按病因划分的肝硬化全球、区域和国家负担：系统分析。
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266. doi: 10.1016/S2468-1253(19)30349-8. Epub 2020 Jan 22.
8
Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.1990 - 2020年按病因划分的死亡率和残疾率的替代预测：全球疾病负担研究
Lancet. 1997 May 24;349(9064):1498-504. doi: 10.1016/S0140-6736(96)07492-2.
9
Measuring the global burden of disease and epidemiological transitions: 2002-2030.衡量2002年至2030年全球疾病负担及流行病学转变
Ann Trop Med Parasitol. 2006 Jul-Sep;100(5-6):481-99. doi: 10.1179/136485906X97417.
10
Emerging innovations in cold plasma therapy against cancer: A paradigm shift.冷等离子体治疗癌症的新兴创新：范式转变。
Drug Discov Today. 2022 Sep;27(9):2425-2439. doi: 10.1016/j.drudis.2022.05.014. Epub 2022 May 19.
引用本文的文献
1
Synthesis, Anticancer Screening, and In Silico Evaluations of Thieno[2,3-]pyridine Derivatives as Hsp90 Inhibitors.噻吩并[2,3 - ]吡啶衍生物作为Hsp90抑制剂的合成、抗癌筛选及计算机模拟评估
Pharmaceuticals (Basel). 2025 Jan 24;18(2):153. doi: 10.3390/ph18020153.
本文引用的文献
1
The Role of ZNF275/AKT Pathway in Carcinogenesis and Cisplatin Chemosensitivity of Cervical Cancer Using Patient-Derived Xenograft Models.利用患者来源的异种移植模型研究ZNF275/AKT通路在宫颈癌发生及顺铂化疗敏感性中的作用
Cancers (Basel). 2023 Nov 28;15(23):5625. doi: 10.3390/cancers15235625.
2
Crosstalk between Microtubule Stabilizing Agents and Prostate Cancer.微管稳定剂与前列腺癌之间的相互作用
Cancers (Basel). 2023 Jun 23;15(13):3308. doi: 10.3390/cancers15133308.
3
Therapies beyond Physiological Barriers and Drug Resistance: A Pilot Study and Review of the Literature Investigating If Intrathecal Trastuzumab and New Treatment Options Can Improve Oncologic Outcomes in Leptomeningeal Metastases from HER2-Positive Breast Cancer.突破生理屏障与耐药性的疗法：一项关于鞘内注射曲妥珠单抗及新治疗方案能否改善HER2阳性乳腺癌软脑膜转移瘤肿瘤学结局的探索性研究及文献综述
Cancers (Basel). 2023 Apr 27;15(9):2508. doi: 10.3390/cancers15092508.
4
HIPK2 as a Novel Regulator of Fibrosis.HIPK2作为纤维化的新型调节因子。
Cancers (Basel). 2023 Feb 7;15(4):1059. doi: 10.3390/cancers15041059.
5
NRF2 and Bip Interconnection Mediates Resistance to the Organometallic Ruthenium-Cymene Bisdemethoxycurcumin Complex Cytotoxicity in Colon Cancer Cells.NRF2与Bip的相互连接介导结肠癌细胞对有机金属钌-对异丙基苯双去甲氧基姜黄素复合物细胞毒性的抗性。
Biomedicines. 2023 Feb 16;11(2):593. doi: 10.3390/biomedicines11020593.
6
PARP Inhibitors and Proteins Interacting with SLX4.聚（ADP-核糖）聚合酶抑制剂与与SLX4相互作用的蛋白质
Cancers (Basel). 2023 Feb 3;15(3):997. doi: 10.3390/cancers15030997.
7
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
8
Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited.PI3K、PARP和WEE1抑制剂靶向治疗联合放疗在人乳头瘤病毒阳性和阴性扁桃体鳞状细胞癌细胞系中的研究显示有协同作用，而APR-246的作用有限。
Cancers (Basel). 2022 Dec 23;15(1):93. doi: 10.3390/cancers15010093.
9
HIPK2 in cancer biology and therapy: Recent findings and future perspectives.HIPK2 在癌症生物学和治疗中的作用：最新发现和未来展望。
Cell Signal. 2023 Jan;101:110491. doi: 10.1016/j.cellsig.2022.110491. Epub 2022 Oct 12.
10
GM-CSF - an oncogenic driver of HER2+ breast leptomeningeal metastasis.粒细胞-巨噬细胞集落刺激因子——HER2阳性乳腺癌软脑膜转移的致癌驱动因素。
Oncoscience. 2022 Oct 10;9:57-59. doi: 10.18632/oncoscience.566. eCollection 2022.
Zotero 插件